Shopping Cart
- Remove All
Your shopping cart is currently empty
p38 MAPK-IN-1
😃Good
Catalog No. T16424Cas No. 1006378-90-0
p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.
p38 MAPK-IN-1
😃Good
Catalog No. T16424Cas No. 1006378-90-0
p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $198 | 8-10 weeks | |
| 5 mg | $347 | In Stock | |
| 25 mg | $1,140 | 8-10 weeks | |
| 50 mg | $1,490 | 8-10 weeks | |
| 100 mg | $1,990 | 8-10 weeks | |
| 1 mL x 10 mM (in DMSO) | $382 | 8-10 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "p38 MAPK-IN-1"
(E)-Ferulic acid methyl ester
Methyl ferulate, Methyl (E)-ferulate
T3S000622329-76-6
(E)-Ferulic acid methyl ester (Methyl (E)-ferulate) is a potential inhibitor of the mitogen-activated phosphor kinase pathway and an anti-inflammatory agent first isolated from the medicinal plant S. tuberosa. Additionally, it shows promising anthelmintic activity against Haemonchus contortus.
- $29
Size
QTY
Adezmapimod
Cited
SB203580, RWJ 64809, PB 203580
T1764152121-47-6
Adezmapimod (SB 203580) is a selective, ATP-competitive p38 MAPK inhibitor (IC50=0.3-0.5 μM) that activates autophagy and mitochondrial autophagy, with more than 100-fold higher selectivity over PKB, LCK, and GSK-3β.
- $30
Size
QTY
Cited(-)-Bornyl acetate
L-(-)-Bornyl acetate, Bornyl acetate
TN14485655-61-8
(-)-Bornyl acetate (L-(-)-Bornyl acetate) is a less active enantiomer of (+)-Bornyl acetate. Isolated from hyssop oil, it possesses antifungal, highly active whitening, and antioxidant properties, and it has potential applications in cosmeceutical materials. It downregulates proinflammatory cytokines in vitro and in vivo, reduces the number of total cells, neutrophils, and macrophages in BALF, attenuates histologic lung alterations, decreases the wet-to-dry weight ratio in BALF, and inhibits the activation of NF-kappa-B inhibitor alpha, extracellular regulated protein kinases, c-JunN-terminal kinase, and p38 mitogen-activated protein kinase.
- $29
Size
QTY
MW-150
MW01-18-150SRM
T54941628502-91-9
MW-150 (MW01-18-150SRM) is a unique, selective, CNS-penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.
- $33
Size
QTY
Bakuchiol
T340010309-37-2
Bakuchiol possesses anti-tumor,and anti-helmenthic properties. It has cytotoxic activity, mainly due to its DNA polymerase1 inhibiting activity. Bakuchiol has anti-bacterial activity against oral pathogens, has great potential for use in food additives and mouthwash for preventing and treating dental caries.
- $80
Size
QTY
p38α inhibitor 3
T67830260428-69-1
p38α inhibitor 3 is a inhibitor of the mitogen-activated protein kinase p38α that can block the effectiveness of myoblast differentiation.
- $38
Size
QTY
Nisin Z
T76264137061-46-2
Nisin Z has anti-inflammatory activity and reduces pro-inflammatory cytokine release by inhibiting activation of the ERK1/2 and p38 mitogen-activated protein kinase (MAPK) signaling pathways, attenuating lipopolysaccharide-induced mastitis through inhibition of the ERK1/2 and p38 mitogen-activated protein kinase signaling pathways.
- $40
Size
QTY
SB 202190 Cited
SB202190, FHPI
T2301152121-30-7
SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
- $35
Size
QTY
Citedp38-α MAPK-IN-1
T12347443913-15-3
p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with an IC50 of 2300 nM in the EFC displacement assay and 5500 nM in the HTRF assay.
- $89
Size
QTY
Doramapimod Cited
BIRB 796
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
- $31
Size
QTY
CitedExarafenib
RAF/KIN_2787
T636442639957-39-2
Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
- $131
Size
QTY
VX-702
479543-46-9
T2513745833-23-2In house
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
- $50
Size
QTY
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production. |
| Targets&IC50 | p38 MAPK:68 nM |
| In vivo | Methods: p38 MAPK-IN-1 (1 mg/kg, intravenous injection and; 10 mg/kg, oral administration) was administered to male wistar rats for in vivo pharmacokinetic study. Results: p38 MAPK-IN-1 had a t1/2 of 7.4 hours and an intravenous CL of 2.7 mL/min/kg. The Cmax of p38 MAPK-IN-1 in male wistar rats after oral administration was 5.3 μM. [1] |
| Molecular Weight | 348.35 |
| Formula | C21H14F2N2O |
| Cas No. | 1006378-90-0 |
| Smiles | O=N=1C=CC=2C(=NC=CC2C=3C=CC(F)=CC3F)C1C=4C=CC=CC4C |
| Relative Density. | 1.27 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (57.41 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy p38 MAPK-IN-1 | purchase p38 MAPK-IN-1 | p38 MAPK-IN-1 cost | order p38 MAPK-IN-1 | p38 MAPK-IN-1 chemical structure | p38 MAPK-IN-1 in vivo | p38 MAPK-IN-1 formula | p38 MAPK-IN-1 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.